Article
Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations.
eLife - 30 Aug 2022
Choudhary Gaurav S, Pellagatti Andrea, Agianian Bogos, Smith Molly A, Bhagat Tushar D, Gordon-Mitchell Shanisha, Sahu Srabani, Pandey Sanjay, Shah Nishi, Aluri Srinivas, Aggarwal Ritesh, Aminov Sarah, Schwartz Leya, Steeples Violetta, Booher Robert N, Ramachandra Murali, Samson Maria, Carbajal Milagros, Pradhan Kith, Bowman Teresa V, Pillai Manoj M, Will Britta, Wickrema Amittha, Shastri Aditi, Bradley Robert K, Martell Robert E, Steidl Ulrich G, Gavathiotis Evripidis, Boultwood Jacqueline, Starczynowski Daniel T, Verma Amit
Abstract excerpt
Background: Mutations in the SF3B1 splicing factor are commonly seen in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), yet the specific oncogenic pathways activated by mis-splicing have not been fully elucidated. Inflammatory immune pathways have been shown to play roles in the pathogenesis of MDS, though the exact mechanisms of their activation in splicing mutant cases are not well understood....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.